Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.

Revenue
+21.8%
EPS
−80.6%
Free cash flow
+6.78%

Quarter to September 2026, against a year earlier

44.61 1.28 −2.79%
Market cap
$7.5B
P/E
0.0×
Fwd P/E
−85.9×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a

Alkermes plc (ALKS) Operating cash flow

Alert me on Operating cash flow

Alkermes plc's operating cash flow for fiscal 2025 was $520.8M, up 18.6% from $439.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $243.0M. Over the past ten years it has ranged from −$63.8M (fiscal 2016) to $520.8M (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. Alkermes plc ranks 14th of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2025 $520.8M 18.59%
FY2024 $439.1M 9.41%
FY2023 $401.4M 1,807.21%
FY2022 $21.0M (79.31%)
FY2021 $101.7M 22.78%
FY2020 $82.8M 14.94%
FY2019 $72.1M (27.40%)
FY2018 $99.3M 417.36%
FY2017 $19.2M —
FY2016 −$63.8M —

Quarterly newest first

Period Operating cash flow Change
Sep 2026 $93.5M (35.61%)
Jun 2026 $145.2M —
Mar 2026 −$165.7M —
Dec 2025 $170.1M 67.27%
43 more quarters

Against its own ten years

Low −$63.8M High $520.8M
Ten-year median $82.8M
Current reading's percentile 100

Operating cash flow against peers

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on ALKS